Bayer(US:BAYRY) Zheng Quan Shi Bao Wang·2025-11-15 11:36Core Insights - Bayer has officially launched the Bayer Yizhuang Open Innovation Center in Beijing on November 15, marking a significant step in its strategy to integrate local innovation with global resources [1] - The center aims to incubate local innovative pharmaceutical companies and enhance the internationalization of Chinese innovations, while collaborating with high-level research institutions to improve basic research and clinical translation capabilities [1] - Bayer Co.Lab has also established its presence at the Yizhuang Open Innovation Center, focusing on deepening local innovation cooperation and accelerating the development of early-stage innovative results and local biotech startups [1][2] Group 1 - The Bayer Yizhuang Open Innovation Center is the first innovation center established by Bayer in China, located in the International Pharmaceutical Innovation Park (BioPark) in Beijing [1] - The center will focus on the integration of industry, education, research, and entrepreneurship, linking "Chinese innovation" with "global wisdom" [1] - Bayer's executives emphasize the importance of local scientific breakthroughs and the center's role in facilitating global access to innovative therapies originating from China [1] Group 2 - The first companies to join Bayer Co.Lab at the Yizhuang Open Innovation Center are Puhe Pharmaceutical and Yaojing Gene, both focusing on innovative drug development [2] - Puhe Pharmaceutical is developing an oral PRMT5 inhibitor targeting MTAP-deficient tumors in collaboration with Bayer [2] - Yaojing Gene is a biotech company dedicated to the research and transformation of gene therapy, with Bayer Co.Lab supporting its exploration of small nucleic acid drug applications [2]